Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

zed, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome. The study will include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy. Up to four dose levels may be evaluated in a serial ascending fashion. Once an optimal or maximal dose is identified, additional patients will be added to confirm clinical observations.

"The clinical trial will be conducted at multiple cancer centers in the United States," said Brian P. Zambrowicz, Ph.D., executive vice president and chief scientific officer at Lexicon. "The clinical trial sites will include The University of Texas M.D. Anderson Cancer Center in Houston, Texas; the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida; and Hematology Oncology Services of Little Rock, Arkansas."

LX1032 is being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.

About LX1032

LX1032 was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. Excessive levels of serotonin have been implicated in symptoms associated with carcinoid syndrome. Serotonin's breakdown product, 5-HIAA, is a biomarker used in the diagnosis of the condition. In preclinical studies, LX1032 reduced peripheral serotonin and urinary 5-HIAA levels in several different species without affecting serotonin levels in the brain. In Phase 1 clinical studies, LX1032 reduced serotonin levels and urinary 5-HIAA in healthy volunteers consistent with preclinical results. LX1032 is being developed for the treatment of gastrointestinal symptoms associated with carcinoid syndrome in patients who
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Jersey (PRWEB) September 30, 2014 ... has been chosen by the Parenteral Drug Association ... 18 and 19, 2014) on container closure integrity testing. ... closure integrity test methods and philosophies detailed in the ... Integrity Evaluation. The course will span container ...
(Date:9/29/2014)... start of the military conflicts in Iraq and Afghanistan, ... States with traumatic brain injury caused by exposure to ... explosive devices, or IEDs. Symptoms of traumatic brain injury ... and nausea, to more severe impairments in memory and ... Defense has recognized the critical importance and complexity of ...
(Date:9/29/2014)... Present-day lithium batteries are efficient but involve a ... from alfalfa (lucerne seed) and pine resin and ... come up with a highly interesting alternative. Their ... journal ChemSusChem . , ,We think our ... energy-efficient solutions for the batteries of the future, ...
(Date:9/29/2014)... Mass. , Sept. 29, 2014  Atlas Venture, ... life sciences and technology innovation, today announced that ... Epizyme (NASDAQ: EPZM ), is joining the ... October 1, 2014. At Atlas, Rhodes will ... groundbreaking companies. He brings an accomplished record in company ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Smart, eco-friendly new battery to solve problems 2Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2
... Software, a leading provider of image data management tools for ... Open Microscopy Environment Consortium, is proud that its founder Professor ... this year,s BBSRC Innovator of the Year. The BBSRC is ... in the non-clinical life sciences, and along with the Wellcome ...
... the best education and to absorb what they are ... the journal Academic Medicine * connects research on how ... real world education, particularly the education of doctors. "Repetition, ... knowing what is happening in the brain will enhance teaching ...
... surgeon Dr. Lewis Groden presented results from a ... and Refractive Surgery (ASCRS) Symposium revealing that LASIK procedures ... and very high patient satisfaction rates. Each ... vision center currently offers patients a choice of multiple ...
Cached Biology Technology:Glencoe Software and Open Microscopy Environment Founder Awarded the BBSRC Innovator of the Year 2011 2Brain scientists offer medical educators tips on the neurobiology of learning 2Brain scientists offer medical educators tips on the neurobiology of learning 3Brain scientists offer medical educators tips on the neurobiology of learning 4Brain scientists offer medical educators tips on the neurobiology of learning 5LasikPlus® Research Reveals Excellent Results From Modern LASIK 2
(Date:9/29/2014)... Joint Genome Institute (DOE JGI), a DOE Office ... new projects have been selected for the 2015 ... to Caribbean waters, and from plant root micro-ecosystems, ... forested watersheds, the CSP 2015 projects portfolio highlights ... extracted. , "These projects catalyze JGI,s strategic ...
(Date:9/29/2014)... can DNA from the skeleton of a man who lived ... us about ourselves as humans? A great deal when his ... in genetic terms found to-date in a region where ... ago. , The man,s maternal DNA, or ,mitochondrial DNA, ... and evolution. Mitochondrial DNA provided the first evidence that we ...
(Date:9/29/2014)... CHAMPAIGN, Ill. Scientists have discovered a previously ... divide, grow and, in the case of estrogen-positive ... the work reveals new targets for breast cancer ... need the most aggressive treatment. , The University ... journal Oncogene . , Estrogen pre-activates the ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... researchers have found that the naturally occurring marine toxin ... in rats exposed to the chemical before birth. Humans ... after eating contaminated shellfish. , The researchers saw ... exposure to domoic acid levels below those generally deemed ...
... (Nasdaq: SLXA) today announced that its researchers in collaboration ... Delaware reported the most comprehensive analysis to date of ... "Elucidation of the Small RNA Component of the Transcriptome," ... the peer-reviewed journal Science. Solexa's assay can be used ...
... Medicine uses PET, radiotracer to track enzyme in smokers, ... in the lungs, possibly contributing to some of smoking's ... the September issue of the Journal of Nuclear Medicine. ... enzyme, also shows that smokers had a lower concentration ...
Cached Biology News:Prenatal exposure to marine toxin causes lasting damage 2Prenatal exposure to marine toxin causes lasting damage 3Solexa and collaborating scientists illuminate the small RNA component of the transcriptome 2Smoking damages key regulatory enzyme in the lung 2Smoking damages key regulatory enzyme in the lung 3
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: